On June 29, 2026, Andrew Levin resigned from the Board of Directors and Breanna O'Reilly, Ph.D., was elected as a new director. Dr. O'Reilly's term expires in 2027 and she will receive an annual cash retainer of $40,000 and a stock option grant of 70,284 shares at an exercise price of $13.36 per share. Climb Bio, Inc. is a biotechnology company focused on developing therapeutic solutions.

Climb Bio, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to offer and sell up to $100.0 million in common stock via an at-the-market offering. Additionally, the company terminated its previous $22.35 million Equity Distribution Agreement with Oppenheimer & Co. Inc. effective June 11, 2026, without incurring any termination penalties. Climb Bio, Inc. is a biotechnology company focused on developing and commercializing therapeutic solutions.

Climb Bio, Inc. announced initial Phase 1b data for budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP). In the 250 mg dose cohort, B-cell depletion averaged over 90% by Week 4 and mean platelet count increased by 111,000 platelets/uL at Week 24. The drug was generally well tolerated with no serious adverse events or treatment discontinuations. Climb Bio, Inc. is a biotechnology company developing monoclonal antibodies for immune-mediated diseases.

At the 2026 Annual Meeting of Stockholders, Climb Bio, Inc. stockholders approved an amendment to the 2021 Equity Incentive Plan to include prefunded warrants in the calculation of the annual share pool increase. Additionally, Alexander (Bo) Cumbo and Douglas Williams, Ph.D., were elected to the Board of Directors, and PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm.